

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q89067

Tohru KAMBE, et al.

Appln. No.: 10/542,724

Group Art Unit: 1626

Confirmation No.: 5408

Examiner: Yong Liang CHU

Filed: July 20, 2005

For: 8-AZAPROSTAGRANDIN DERIVATIVES AND MEDICAL USE THEREOF

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

ATTN: MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REMARKS

Applicant offers the following comments in response to the Examiner's Statement of Reasons for Allowance set forth on pages 2-3 of the Notice of Allowability dated February 23, 2007.

Cameron et al. does not specifically disclose the two compounds set forth at page 3 of the Notice of Allowability. Further, Applicant believes that the second of the two compounds does not even fall within the general formula (I) described in Cameron et al. The compound relied

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

U.S. Application No. 10/542,724

Atty. Docket No. Q89067

upon by the Examiner in the Office Action was that of Example 5A of Cameron et al. (See page 2 of the Notice of allowability dated October 2, 2006.)

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE

65565

CUSTOMER NUMBER

Date: May 22, 2007